- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02366013
Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine
A Phase 1 Clinical Trial of the Safety and Immunogenicity of an Oral, Replicating Adenovirus 26 Vector Vaccine for HIV-1 (rcAd26.MOS1.HIV-Env) in Healthy HIV-1-uninfected Adults
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This study is a phase I dose-escalation randomized, double blind, placebo-controlled study designed to evaluate the safety and immunogenicity of rcAd26.MOS1.HIV-Env, an oral replicating adenovirus 26 vector vaccine in healthy HIV-1 uninfected adults. The vaccine will be administered orally at a single time point (Day 0) at one of four dose levels depending on study group: 1 x 10^8 virus particles (vp), 1 x 10^9 vp, 1 x 10^10 vp and 1 x 10^11 vp. Volunteers will be randomized to vaccine: placebo in a 5:1 ratio in each group.
Volunteers will be screened up to 56 days before vaccination and will be followed for 12 months after vaccination.
Because the vaccine is replication competent, volunteers will be housed in an isolation unit from day -2 through day 9. Household contacts will also be enrolled and tested for possible transmission.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
New York
-
Rochester, New York, Förenta staterna, 14642
- University of Rochester
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age 18-40 years old.
- Ability and willingness to provide informed consent.
- Complete an assessment of understanding
- Available for the duration of the trial, including willingness to be kept in an isolation facility
- From Day 10 through 4 months following vaccination must reside alone or with no more than 2 adults (age 18-60) and no minors under age 18
- Good general health as shown by medical history, physical exam, and screening
- Willing to undergo HIV testing and willing to receive risk reduction counseling
- All female volunteers must be willing to undergo urine pregnancy tests
- Sexually active males must be willing to use an effective method of contraception until at least 4 months after vaccination
- Women of child bearing potential commit to use an effective method of contraception when sexually active with males for 4 months after vaccination
- Willing to forgo donations of blood or any other tissues during the study and, for those who test HIV positive due to trial vaccination (vaccine-induced HIV seroreactivity), until the anti-HIV antibody titers become undetectable
- Low risk for HIV infection and willing to maintain low-risk behavior for the trial duration
Exclusion Criteria:
- Confirmed HIV-1 or HIV-2 infection; confirmed HCV, HBV, or syphilis infection
- Current or planned participation in another clinical trial of an experimental agent during the study period
- Pregnant or lactating
- Significant acute or chronic disease, including inflammatory bowel disease or other chronic gastrointestinal disease, immunodeficiency syndrome, or condition requiring immunosuppressant medications
- Use of anticancer, antituberculosis or other medications considered significant by the investigator within the previous 6 months
- Receipt of live-attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with Investigational Product (within 14 days for live attenuated influenza vaccine [LAIV]); or receipt of other vaccine (e.g., influenza, pneumococcal), allergy treatment with antigen injections or tuberculin skin test within the previous 14 days or planned receipt within 14 days after vaccination with Investigational Product
- Receipt of blood transfusion or blood-derived products within the previous 3 months
- Receipt of HIV vaccine(s) in a prior HIV vaccine trial.
- Previous severe local or systemic reactions to vaccination
- History of splenectomy
- History of seizure in the last 3 years
- Known autoimmune disease
- Asthma other than mild, well-controlled asthma.
- Diabetes mellitus type 1 or type 2
- Thyroidectomy, or thyroid disease requiring medication during the last 12 months
- Angioedema within the last 3 years if episodes are considered serious or have required medication within the last 2 years
- Hypertension
- Body mass index (BMI) ≥ 40
- Bleeding disorder diagnosed by a doctor
- Malignancy (Not excluded: a volunteer with a surgical excision and subsequent observation period that in the investigator's estimation has a reasonable assurance of sustained cure or is unlikely to recur during the study period)
- Psychiatric condition that compromises safety of the volunteer or precludes compliance with the protocol
- All healthcare workers with direct patient contact
- Childcare worker who has direct contact with children
- Individuals employed as food handlers or otherwise engaged in the preparation or delivery of food outside of their place of residence
- Positive urine toxicology test
Household contacts 18-60 years of age are also evaluated for eligibility with a more abbreviated list of inclusion/exclusion criteria.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Group 1
1 dose of rcAd26.MOS1.HIV-Env 1x10^8 vp or placebo
|
1 oral capsule, 1x10^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
|
Experimentell: Group 2
1 dose of rcAd26.MOS1.HIV-Env 1x10^9 vp or placebo
|
10 oral capsules, 1x10^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
|
Experimentell: Group 3
1 dose of rcAd26.MOS1.HIV-Env 1x10^10 vp or placebo
|
1 oral capsule, 1x10^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
|
Experimentell: Group 4
1 dose of rcAd26.MOS1.HIV-Env 1x10^11 vp or placebo
|
10 oral capsules, 1x10^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Safety and tolerability as measured by number of volunteers reporting the following:
Tidsram: 4 Months post-vaccination
|
|
4 Months post-vaccination
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Proportion (95%CI) of volunteers per dose group with positive shedding responses and mean response per group with 95% CI.
Tidsram: 28 days
|
o Rectal/oral shedding: real-time PCR for rcAd26.MOS1.HIV-Env at 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 17, 21, 7, 12, 21, and 28 days after vaccination.
|
28 days
|
Proportion of volunteers per dose group with positive immunological responses and mean response (e.g. GMT) per group with 95% CI.
Tidsram: 12 Months
|
|
12 Months
|
Samarbetspartners och utredare
Utredare
- Studiestol: Kathryn Stephenson, MD, MPH, Beth Israel Deaconess Medical Center
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- rcAd001/IAVI R001
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekryteringHIV | HIV-testning | HIV-koppling till vård | HIV-behandlingFörenta staterna
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationAvslutadPartners HIV-testning | Hiv-rådgivning för par | Par kommunikation | Hiv-incidensKamerun, Dominikanska republiken, Georgien, Indien
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement och andra samarbetspartnersOkändHIV | HIV-oinfekterade barn | Barn som utsätts för HIVKamerun
-
University of MinnesotaIndragenHIV-infektioner | HIV/AIDS | Hiv | AIDS | Aids/Hiv problem | AIDS och infektionerFörenta staterna
-
University of Maryland, BaltimoreIndragenHiv | Njurtransplantation | HIV-reservoar | CCR5Förenta staterna
-
Hospital Clinic of BarcelonaAvslutadIntegrashämmare, HIV; HIV PROTEAS HÄMMARSpanien
-
Erasmus Medical CenterHar inte rekryterat ännuHIV-infektioner | Hiv | HIV-1-infektion | HIV I-infektionNederländerna
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London och andra samarbetspartnersRekryteringHIV | HIV-testning | Koppling till vårdSydafrika
-
National Taiwan UniversityRekrytering
-
Helios SaludViiV HealthcareOkändHiv | HIV-1-infektionArgentina
Kliniska prövningar på rcAd26.MOS1.HIV-Env 1x10^8 vp
-
Merck Sharp & Dohme LLCAvslutad
-
Roswell Park Cancer InstituteRekryteringLung-småcelligt karcinom i omfattande stadiumFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Avslutad
-
National Cancer Institute (NCI)AvslutadAnaplastiskt storcelligt lymfom, ALK-positivt | Ann Arbor Steg II Nonkutan Childhood Anaplastic Large Cell Lymfom | Ann Arbor Stage III Nonkutan Childhood Anaplastic Large Cell Lymfom | Ann Arbor Steg IV Nonkutant Childhood Anaplastic Large Cell LymfomFörenta staterna
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeAkut lymfoblastisk leukemi | Återkommande akut lymfatisk leukemi hos vuxna | Vuxen B Akut lymfoblastisk leukemi | Vuxen T Akut lymfoblastisk leukemi | Vuxen B Akut lymfoblastisk leukemi med t(9;22)(q34.1;q11.2); BCR-ABL1 | Vuxen L1 Akut lymfoblastisk leukemi | Vuxen L2 Akut lymfoblastisk leukemiFörenta staterna
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeB Akut lymfoblastisk leukemi | Leukemi i centrala nervsystemet | Testikelleukemi | B Akut lymfoblastisk leukemi, BCR-ABL1-liknandeFörenta staterna, Kanada, Puerto Rico, Australien, Nya Zeeland, Schweiz, Irland
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeVuxen T Akut lymfoblastisk leukemi | Barndom T Akut lymfoblastisk leukemi | Ann Arbor Steg II vuxen lymfoblastiskt lymfom | Ann Arbor Stage II barndomslymfoblast lymfom | Ann Arbor Steg III vuxen lymfoblastiskt lymfom | Ann Arbor stadium III barndomslymfoblast lymfom | Ann Arbor Steg IV Lymfoblast... och andra villkorFörenta staterna, Kanada, Australien, Nya Zeeland